A 14-Day Double-Blind, Randomized, Controlled Crossover Intervention Study with Anti-Bacterial Benzyl Isothiocyanate from Nasturtium ( Tropaeolum majus ) on Human Gut Microbiome and Host Defense.
Simon P PfäffleCorinna HerzEva BrombacherMichele ProiettiMichael GiglChristoph K HofstetterVerena K Mittermeier-KleßingerSophie ClaßenHoai Thi Thu TranCorinna DawidClemens KreutzStefan GüntherEvelyn LamyPublished in: Nutrients (2024)
Despite substantial heterogeneity of studies, there is evidence that antibiotics commonly used in primary care influence the composition of the gastrointestinal microbiota in terms of changing their composition and/or diversity. Benzyl isothiocyanate (BITC) from the food and medicinal plant nasturtium ( Tropaeolum majus ) is known for its antimicrobial activity and is used for the treatment of infections of the draining urinary tract and upper respiratory tract. Against this background, we raised the question of whether a 14 d nasturtium intervention (3 g daily, N = 30 healthy females) could also impact the normal gut microbiota composition. Spot urinary BITC excretion highly correlated with a weak but significant antibacterial effect against Escherichia coli . A significant increase in human beta defensin 1 as a parameter for host defense was seen in urine and exhaled breath condensate (EBC) upon verum intervention. Pre-to-post analysis revealed that mean gut microbiome composition did not significantly differ between groups, nor did the circulating serum metabolome. On an individual level, some large changes were observed between sampling points, however. Explorative Spearman rank correlation analysis in subgroups revealed associations between gut microbiota and the circulating metabolome, as well as between changes in blood markers and bacterial gut species.
Keyphrases
- double blind
- randomized controlled trial
- placebo controlled
- primary care
- escherichia coli
- endothelial cells
- respiratory tract
- single cell
- urinary tract
- clinical trial
- open label
- induced pluripotent stem cells
- phase iii
- study protocol
- risk assessment
- phase ii
- climate change
- pseudomonas aeruginosa
- innate immune
- anti inflammatory
- multidrug resistant
- general practice